FIGURE

Fig. 1

ID

ZDB-FIG-240910-14

Publication

Gu et al., 2024 - Therapeutic liposomal combination to enhance chemotherapy response and immune activation of tumor microenvironment

Other Figures

All Figure Page

Back to All Figure Page

Fig. 1

Illustration of the liposome-mediated immunochemotherapy. Neutral liposomes carried oxaliplatin (OLP) kill cancer cells directly and induce immunogenic cell death (ICD), which provide potent pro-inflammatory signals for DCs to be activated and recruited from the lymph nodes. This process initiates the anti-tumor immunity and employs effector T cells in the tumor tissue. Meanwhile, the stimulation of the TLR pathway by PRLP liposomes leads to the release of cytokines such as IL-12, IFN-γ, TNF-α, etc., which also aims to polarize the tumor-associated macrophages towards the pro-inflammatory M1 subtype. The engagement of M1 macrophages and effector T cells in the TME can inhibit tumor growth more effectively and overcomes oxaliplatin resistance mechanisms in CT26-tumor bearing mice.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Control Release